Hyundai Bioscience Co. Ltd Total Assets
Hyundai Bioscience Co. Ltd total assets. Based on the latest financial reports, Hyundai Bioscience Co. Ltd (048410) holds total assets worth ₩131.31 Billion KRW (≈ $88.98 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Hyundai Bioscience Co. Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Hyundai Bioscience Co. Ltd (2002–2025)
Total assets of Hyundai Bioscience Co. Ltd from 2002 to 2025. This chart illustrates how Hyundai Bioscience Co. Ltd's total assets have evolved over time, based on quarterly financial data. See Hyundai Bioscience Co. Ltd stock quote for real-time trading data and today's change.
Hyundai Bioscience Co. Ltd - Asset Composition Analysis
Hyundai Bioscience Co. Ltd Total Assets Breakdown (December 2025)
Hyundai Bioscience Co. Ltd total assets breakdown as of December 2025. Hyundai Bioscience Co. Ltd's total assets of ₩131.31 Billion consist of 33.7% current assets and 66.4% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 17.1% |
| Accounts Receivable | ₩2.32 Billion | 1.8% |
| Inventory | ₩1.14 Billion | 0.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩52.17 Billion | 39.9% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2002–2025)
This chart illustrates how Hyundai Bioscience Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Hyundai Bioscience Co. Ltd working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hyundai Bioscience Co. Ltd's current assets represent 33.7% of total assets in 2025, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 17.1% of total assets in 2025, up from 9.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, an increase from 2.0% in 2002.
- Asset Diversification: The largest asset category is intangible assets at 39.9% of total assets.
Hyundai Bioscience Co. Ltd Competitors by Total Assets
Key competitors of Hyundai Bioscience Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Hyundai Bioscience Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.36 | 8.38 | 1.81 |
| Quick Ratio | 2.32 | 8.02 | 1.62 |
| Cash Ratio | 0.00 | 0.00 | 0.19 |
| Working Capital | ₩25.27 Billion | ₩34.52 Billion | ₩17.36 Billion |
Hyundai Bioscience Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Hyundai Bioscience Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.26 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 93.1% |
| Total Assets | ₩130.74 Billion |
| Market Capitalization | $356.42 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hyundai Bioscience Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Hyundai Bioscience Co. Ltd's assets grew by 93.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Hyundai Bioscience Co. Ltd (2002–2025)
The table below shows the annual total assets of Hyundai Bioscience Co. Ltd from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩130.74 Billion ≈ $88.60 Million |
+93.10% |
| 2024-12-31 | ₩67.70 Billion ≈ $45.88 Million |
+28.25% |
| 2023-12-31 | ₩52.79 Billion ≈ $35.78 Million |
-21.59% |
| 2022-12-31 | ₩67.33 Billion ≈ $45.63 Million |
-16.39% |
| 2021-12-31 | ₩80.53 Billion ≈ $54.57 Million |
-12.76% |
| 2020-12-31 | ₩92.31 Billion ≈ $62.56 Million |
+45.98% |
| 2019-12-31 | ₩63.24 Billion ≈ $42.85 Million |
+17.08% |
| 2018-12-31 | ₩54.01 Billion ≈ $36.60 Million |
+9.11% |
| 2017-12-31 | ₩49.50 Billion ≈ $33.54 Million |
-7.27% |
| 2016-12-31 | ₩53.38 Billion ≈ $36.18 Million |
+22.96% |
| 2015-12-31 | ₩43.41 Billion ≈ $29.42 Million |
+32.33% |
| 2014-12-31 | ₩32.81 Billion ≈ $22.23 Million |
+6.37% |
| 2013-12-31 | ₩30.84 Billion ≈ $20.90 Million |
-3.80% |
| 2012-12-31 | ₩32.06 Billion ≈ $21.73 Million |
+5.21% |
| 2011-12-31 | ₩30.47 Billion ≈ $20.65 Million |
-37.11% |
| 2010-12-31 | ₩48.45 Billion ≈ $32.83 Million |
-20.81% |
| 2009-12-31 | ₩61.19 Billion ≈ $41.46 Million |
-30.09% |
| 2008-12-31 | ₩87.53 Billion ≈ $59.31 Million |
-15.16% |
| 2007-12-31 | ₩103.16 Billion ≈ $69.91 Million |
-2.23% |
| 2006-12-31 | ₩105.52 Billion ≈ $71.51 Million |
-54.29% |
| 2005-12-31 | ₩230.83 Billion ≈ $156.43 Million |
+2.68% |
| 2004-12-31 | ₩224.80 Billion ≈ $152.34 Million |
-7.32% |
| 2003-12-31 | ₩242.55 Billion ≈ $164.37 Million |
+20.91% |
| 2002-12-31 | ₩200.60 Billion ≈ $135.94 Million |
-- |
About Hyundai Bioscience Co. Ltd
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.